Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients

Reina-Ortiz, C. ; Constantinides, M. ; Fayd-Herbe-de-Maudave, A. ; Présumey, J. ; Hernandez, J. ; Cartron, G. ; Giraldos, D. ; Díez, R. ; Izquierdo, I. (Universidad de Zaragoza) ; Azaceta, G. (Universidad de Zaragoza) ; Palomera, L. (Universidad de Zaragoza) ; Marzo, I. (Universidad de Zaragoza) ; Naval, J. (Universidad de Zaragoza) ; Anel, A. (Universidad de Zaragoza) ; Villalba, M.

Resumen: In this study we evaluated the potential of expanded NK cells (eNKs) from two sources combined with the mAbs daratumumab and pembrolizumab to target primary multiple myeloma (MM) cells ex vivo. In order to ascertain the best source of NK cells, we expanded and activated NK cells from peripheral blood (PB) of healthy adult donors and from umbilical cord blood (UCB). The resulting expanded NK (eNK) cells express CD16, necessary for carrying out antibody-dependent cellular cytotoxicity (ADCC). Cytotoxicity assays were performed on bone marrow aspirates of 18 MM patients and 4 patients with monoclonal gammopathy of undetermined significance (MGUS). Expression levels of PD-1 on eNKs and PD-L1 on MM and MGUS cells were also quantified. Results indicate that most eNKs obtained using our expansion protocol express a low percentage of PD-1+ cells. UCB eNKs were highly cytotoxic against MM cells and addition of daratumumab or pembrolizumab did not further increase their cytotoxicity. PB eNKs, while effective against MM cells, were significantly more cytotoxic when combined with daratumumab. In a minority of cases, eNK cells showed a detectable population of PD1+ cells. This correlated with low cytotoxic activity, particularly in UCB eNKs. Addition of pembrolizumab did not restore their activity. Results indicate that UCB eNKs are to be preferentially used against MM in the absence of daratumumab while PB eNKs have significant cytotoxic advantage when combined with this mAb.

Idioma: Inglés

DOI: 10.1080/2162402X.2020.1853314

Año: 2021

Publicado en: OncoImmunology 10, 1 (2021), 1853314 [11 pp]
ISSN: 2162-4011

Factor impacto JCR: 7.723 (2021)

Categ. JCR: ONCOLOGY rank: 48 / 245 = 0.196 (2021) - Q1 - T1
Categ. JCR: IMMUNOLOGY rank: 40 / 163 = 0.245 (2021) - Q1 - T1

Factor impacto CITESCORE: 13.3 - Immunology and Microbiology (Q1) - Medicine (Q1)

Factor impacto SCIMAGO: 2.096 - Immunology and Allergy (Q1) - Immunology (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2016-76338-R

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)